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Abstract
Background: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting
pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size,
somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).
Methods: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery.
Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with
less than 50% of GH reduction were considered as SSA nonresponders. We analyzed the miRNAs in 21 GH-
secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed
miRNAs were validated by quantitative real-time PCR.
Results: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal
pituitaries. Differential expression of 9 miRNAs was observed between micro- and macro-adenomas. Thirteen
miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from
lanreotide-untreated patients. Seven miRNAs were differentially expressed between SSA responders or GH
nonresponders. Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and
progression.
Conclusions: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas
transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA. Identification
and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the
pathogenesis of pituitary adenoma.
Background
MicroRNAs (miRNAs) are a class of non-coding RNAs
that post-transcriptionally regulate the expression of
downstream mRNAs by targeting the 3’ untranslated
regions [1,2]. Since the discovery that miRNAs are a
class of conserved genes, hundreds of miRNA genes
have been identified. More than 6000 miRNAs encoded
by virus, plant and animal species have been recorded in
miRBase bank [3,4]. miRNAs are a huge class of nega-
tive gene regulators controlling a wide range of biologi-
cal functions such as cell proliferation, differentiation,
signaling pathways, apoptosis and metabolism [5,6].
Recently, it has been shown that several human cancers,
e.g. breast, colon, lung, brain, thyroid, and hematologic
malignancies are associated with altered miRNAs
expression [7]. In addition, more and more evidences
suggested that some miRNAs might have oncogenic or
tumor suppressor functions [8], and play an important
role in tumorigenesis [9]. Previous studies have shown
that expression of miR-15a and miR-16-1 in pituitary
adenomas is lower than that in the normal pituitary tis-
sues. Further more, the expression level of miR-15a and
miR-16-1 is inversely correlated with tumor diameter
and directly correlated with the secretion of the anti-
neoplastic cytokine p43 [10]. Further studies have
demonstrated that several identified miRNAs are
involved in cell proliferation, apoptosis and cortico-
trophic tumorigenesis, suggesting that deregulation of
* Correspondence: zhuyongh@mail.sysu.edu.cn; mmh222111@yahoo.com.cn
1Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated
Hospital, Sun Yat-sen University, Guangzhou 510080, China
2Department of Histology and Embryology, Zhongshan School of Medicine,
Sun Yat-sen University, Guangzhou 510080, China
Full list of author information is available at the end of the article
Mao et al. Diagnostic Pathology 2010, 5:79
http://www.diagnosticpathology.org/content/5/1/79
© 2010 Mao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.miRNAs expression may be involved in pituitary tumori-
genesis [11,12]. Predictive miRNAs could be potentially
useful diagnostic markers, improving the classification of
pituitary adenomas. Nevertheless, the role of transcrip-
tional regulation of miRNAs and their target genes in
the pathogenesis of pituitary adenomas remains largely
unknown. Development of acromegaly is caused by the
proliferation of somatotrophs and oversecretion of the
hormone. A cascade of transcription factors and genetic
elements normally determine the ability of somatotroph
cells to synthesize and secrete growth hormone [13]. In
this study, we compared the miRNAs expression
between GH-secreting pituitary adenomas samples and
normal pituitary samples by miRCURY™ Locked Nucleic
Acid Array in order to identify miRNAs that are specifi-
cally associated with GH-secreting pituitary adenomas.
T h ep o s s i b l er o l eo ft h e s ei d e n t i f i e dm i R N A sw a sa l s o
discussed.
Materials and methods
Patient information
The study was approved by the Institutional Review
Board of the First Affiliated Hospital, Sun Yat-sen Uni-
versity (Guanzhou, China). The local ethical committee
approved the pre-surgical medical treatment and all par-
ticipants had informed written consent. The study is
registered at ClinicalTrials.gov (NCT00993356). Tissue
samples were collected in accordance with the guide-
lines of local committee on human research. The biolo-
gical diagnosis of acromegaly was based on the criteria
that (1) plasma GH concentration is higher than 1 μg/l
after oral administration of 75 g of glucose (oral glucose
tolerance test, OGTT); (2) insulin-like growth factor 1
(IGF-1) concentration is increased compared to the nor-
mal population in the same age and sex; and (3) relevant
clinical features associated with acromegaly occurred
and pituitary adenoma appeared on the magnetic reso-
nance imaging examination.
Experimental design
We examined 21 GH-secreting pituitary adenoma sam-
ples and found that 3 samples belonged to micro-adeno-
mas (maximum diameter <10 mm), while the other 18
samples were macro-adenomas (maximum diameter >10
mm) [14]. Fifteen patients were treated with lanreotide
(Somatuline Autogel, Beaufour Ipsen, Paris, France) for
4 months before surgery. Six patients did not receive
any pre-surgical medical treatments. Previous conven-
tional or stereotaxic (Gamma knife) radiotherapy was
not performed for all the patients. Patients treated with
lanreotide presented no evidence of previous cholecysto-
lithiasis or any other abnormalities. As reported by
Maiza, the initial dosage of lanreotide was 60 mg/28
days [15]. Patients with >50% reduction of GH secretion
after treatment with lanreotide were considered as SSA
responders, while patients with <50% GH secretion were
considered as SSA nonresponders [16]. We assessed the
responsiveness of GH secretion after the second injec-
tion because of the slow-release of lanreotide formula-
tions. The dosage of lanreotide was adjusted according
to the hormone response. In the case of nonresponders,
the dosage of lanreotide was increased to 90 mg/28
days, and the dosage of lanreotide was maintained at
60 mg/28 days in the case of responders. SSA nonre-
sponding patients received the treatment of lanreotide
continuously because it ameliorated the clinical symp-
toms including headache, fatigue and peripheral soft-
tissue swelling. All patients were well tolerated by
lanreotide and they all completed the study. Twelve
patients experienced bowel cramps and diarrhoea for
several days after the first injection of lanreotide and the
symptoms were resolved after the third injection. No
adverse events were reported during the study. Magnetic
resonance imaging scan of the pituitary, detection of
plasma GH and IGF-1 concentration were performed
after treatment.
Detection of miRNAs expression and data analysis
Pituitary tumor samples were obtained during transphe-
noidal surgery. Tumor samples were divided two parts:
one was used for pathologic analysis including hematox-
ylin eosin (H&E) and immunohistochemical staining
and another was used for miRNAs expression. Tumor
samples were snapped-frozen and stored at -80Ω°C.
RNA isolation was performed according to the protocols
provided by the manufacturer. Immunohistochemical
staining for anterior pituitary hormones was performed
on all samples to confirm hormone activity. Primary
antibodies against the following antigens were used: pro-
lactin (PRL, polyclonal, Code No A0569, 1:200, Dako),
growth hormone (GH, polyclonal, Code No A0570,
1:400, Dako), follicle stimulating hormone (FSH, mono-
clonal, Code M3504, 1:50, Dako), luteinizing hormone
(LH, monoclonal, Code M3502, 1:50, Dako), thyroid-sti-
mulating hormone (TSH, monoclonal, Code M3503,
1:50, Dako), adrenocorticotropic hormone (ACTH,
monoclonal, Code M3501, 1:50, Dako). In this study, all
samples showed immunoreactivity of GH and negative
for PRL, TSH, ACTH, FSH and LH. For miRNAs
expression, tumor samples were micro-dissected by an
experienced pathologist to remove any non-tumor tis-
s u e s .A sc o n t r o l ,6n o r m a lp i tuitaries were obtained
from the accidental death subjects during autopsies
within six hours. There was no evidence of any previous
endocrine diseases or other abnormalities in these acci-
dental death subjects. All the sample tissues were dis-
rupted by the Biopulverizer (biospec, Bartlesville, USA)
and homogenized using the Mini-Bead-Beater-16
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Page 2 of 8(biospec). Total RNAs were isolated by using TRIzol
reagent (Invitrogen, Carlabad, CA) and RNeasy mini kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instruction. The quality and quantity of RNA were mea-
sured using a NanoDrop ND-1000 (NanoDrop). The
ratio of OD260/280 for pure RNA should be close to 2.0
(ratios between 1.8 and 2.1 are acceptable). The ratio of
OD260/230 should be larger than 1.8.
After the measurement of RNA quantity and quality,
the samples are labeled using the miRCURY™ Hy3™/Hy5™
Power labeling kit (Exiqon, Denmark) according to the
manufacturer’s instruction. The Hy3™/Hy5™-labeled RNA
molecules were hybridized on the miRCURY™ LNA
Array (Exiqon, Denmark). The latest version of the array
(v.10.0) consists of control probes, mismatched probes
and more than 1200 capture probes, which cover all
human, mouse and rat miRNAs sequences annotated in
miRBase 10.0 at The Wellcome Trust Sanger Institute.
Scanning was performed with the Axon GenePix 4000B
microarray scanner. GenePix Pro 6.0 software (Axon
Instruments, Union City, CA) was used to analyze the
raw intensity of the images. Each sample was hybridized
with miRCURY LNA™ Arrays in triplicate with three
independent samples. The intensity of green signal was
calculated after background subtraction and four repli-
cated spots of each probe on the same slide were aver-
aged. We used median normalization method to obtain
“normalized data” based on the following formula: nor-
malized data = (foreground-background)/median. The
median is 50 percent quantile of the miRNA intensity,
which was larger than 50 in all samples after background
correction. After normalization, student t-test was used
to identity the miRNAs that were differentially expressed
between tumor and normal samples. Unsupervised hier-
archical clustering and correlation analyses were per-
formed for the miRNAs data. The differential expression
of miRNAs was based on the criteria that (1) up- or
down-regulated miRNAs were fold change >2.00 or
<0.50, respectively; (2) the threshold value of false discov-
ery rate (FDR) <0.10.
Quantitative Real Time PCR
For quantitative real time PCR (qRT-PCR), total RNAs
were extracted from pituitary adenomas with TRIzol
reagent, digested with DNase I and reverse-transcribed
into cDNA using applied biosystems 9700 Thermocycler
(Applied Biosystems). The reverse transcription con-
tained 1 μg of purified total RNAs, 2 μlo fd N T P
(2.5 mM each), 2 μl of RT Buffer (Epicentre), 1 μlo fR T
Prime (1 μM), 2 μl of MMLV reverse transcriptase and
0.3 μl of RNase inhibitor mix in a 20 μl volume. Reverse
transcription was performed at 16°C for 30 min, 42°C
for 30 min and 85°C for 5 min. All reverse transcription
reactions were run in duplicate. qRT-PCR was
performed using a standard TaqMan PCR kit protocol
on the applied biosystems 7700 sequence detection sys-
tem (Applied Biosystems). The 25 μl PCR included 2 μl
of RT product, 1×TaqMan Universal PCR Master Mix
(Applied Biosystems) according to the manufacturer’s
instruction. The reactions were incubated in a 96-well
plate at 95°C for 5 min, followed by 40 cycles of 95°C
for 10 sec, 60°C for 20 sec and 72°C for 20 sec. All reac-
tions were run in triplicates for each data point, and
data analysis was performed by using Sequence Detec-
tion System 1.9.1 software (Applied Biosystems). Primers
used for qRT-PCR are listed in Additional file 1:
Table S1. U6 was used as endogenous control to nor-
malize the expression level of target genes because preli-
minary experiments showed that U6 expression level
was very constant in all samples. Data was normalized
by the endogenous control U6 Ct-median expression
a n dc a l i b r a t e db y
ΔCt-median value obtained from all
sample tissues. Relative quantification of miRNA expres-
sion was calculated using the 2
-ΔΔCT method [17].
We selected these miRNAs, such as miR-125a-5p,
miR-125b, miR-524-5p etc, for qRT-PCR verification
because these miRNAs were involved in the regulation
of pituitary tumor-transforming gene (PTTG), insulin-
like growth factor-binding protein 3 (IGFBP-3) and
insulin-like growth factor-binding protein complex acid
labile subunit chain precursor (IGFALS) based on the
miRBase targets bank. We were particularly interested
in the function of these miRNAs and their targets in the
future research. Another reason that we selected these
miRNAs for qRT-PCR was that some of these miRNAs
were also reported to be differentially expressed in pre-
vious studies [11,12].
Results
The diagnosis of GH-secreting pituitary adenoma was
confirmed by H&E and immunohistochemical staining
for all the samples (Additional file 2: Figure 1). In the
15 patients treated with lanreotide, 12 patients were
considered as SSA responders and the remaining
3 patients were SSA nonresponders. The GH, IGF-1
l e v e la n dt h ev o l u m eo ft u m o r sb e f o r ea n da f t e rl a n r e o -
tide treatment were list in Additional file 1: Table S2.
Significant shrinkage of the tumor volume was observed
in two patients after treatment, we have published it in
European Journal of Endocrinology [18].
A total of 52 miRNAs were differentially expressed
between GH-secreting pituitary adenomas and normal
pituitaries. Twenty-three miRNAs were up-regulated and
twenty-nine miRNAs were down-regulated in GH-secret-
ing pituitary adenomas (Table 1). Although, the fold
change of some up- and down-regulated miRNAs was
>2.00 or <0.50, the miRNAs are not listed in Table 1
because the P value was >0.05 (miR-183, up, 2.73,
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Page 3 of 8P = 0.12, FDR = 0.021; miR-222, up, 2.87, P = 0.23, FDR =
0.023; miR-516b, up, 2.48, P = 0.16, FDR = 0.065; miR-
601, up, 2.67, P = 0.11, FDR = 0.094; miR-629, up, 2.71,
P = 0.31, FDR = 0.212; miR-886-5p, up, 3.49, P = 0.09,
FDR = 0.025; miR-766, 2.53, P = 0.18, FDR = 0.033; miR-
124, down, 0.29, P = 0.27, FDR = 0.005; miR-125a-5p,
down, 0.41, P = 0.16, FDR = 0.029; miR-15a, down, 0.32,
P = 0.21, FDR = 0.076; miR-198, down, 0.36, P =0 . 2 5 ,
FDR = 0.005; miR-630, down, 0.39, P = 0.26, FDR = 0.095;
miR-744, down, 0.43, P = 0.24, FDR = 0.072; miR-765,
down, 0.37, P = 0.14, FDR = 0.173). Cluster analysis
showed a clear distinction between pituitary adenomas
and normal pituitary (Figure 1). When adding the thresh-
old value of FDR <0.10 to the differentially expressed cri-
teria, eight miRNAs lost their status of differentially
expressed (five in Table 1, two in Table 2 and one in
Table 3).
A total of 9 miRNAs were differentially expressed
between macro- and micro-adenomas (Table 3). Cluster
analysis based on these differentially expressed miRNAs
showed that macro- and micro-adenomas belonged to
two distinct groups (Figure 2). A total of 13 miRNAs
were differentially expressed between the GH-secreting
pituitary adenomas with lanreotide-treated patients and
those without lanreotide-treatment (Table 2). We also
found that 7 miRNAs were differentially expressed
between SSA responders and SSA nonresponders (Table
4). Cluster analysis based on these differentially
expressed miRNAs showed a clear distinction between
SSA responders and SSA nonresponders (Figure 3).
To verify the results obtained by microarray analysis,
we performed qRT-PCR for some of the differentially
expressed miRNAs. qRT-PCR results for the expression
of miR-124, miR-125a, miR-126, miR-223, miR-381,
miR-503, miR-524-5p, miR-525-5p, and miR-886-5p
were consistent with the results obtained from microar-
ray analysis (Table 5). In supplementary experiments,
we performed qRT-PCR for analyzing more miRNAs
Figure 1 Cluster analysis shows a clear distinction between
GH-secreting pituitary adenomas and normal pituitary. GH-
secreting pituitary adenomas: 1-21, Normal pituitary: 22-27.
Table 1 miRNAs differentially expressed in GH-secreting
pituitary adenomas vs. normal pituitaries
Up regulated Down regulated
Name Fold P value FDR Name Fold P value FDR
miR-136 3.52 0.005 0.005 miR-125b 0.16 0.035 0.033
miR-15b 4.29 0.021 0.062 miR-126 0.39 0.048 0.013
miR-184 2.17 0.033 0.033 miR-145 0.42 0.023 0.005
miR-194 2.13 0.047 0.029 miR-17 0.39 0.047 0.083
miR-200c 5.07 0.004 0.066 miR-185 0.25 0.012 0.023
miR-297 3.15 0.002 0.051 miR-192 0.12 0.005 0.046
miR-29b-1 2.39 0.042 0.016 miR-193a-3p 0.23 0.000 0.027
miR-32 5.48 0.030 0.020 miR-193a-5p 0.25 0.049 0.016
miR-340 5.69 0.004 0.066 miR-200b 0.41 0.002 0.061
miR-365 8.43 0.002 0.061 miR-302c 0.19 0.026 0.073
miR-378 3.79 0.046 0.077 miR-30a 0.43 0.000 0.027
miR-486-5p 4.28 0.043 0.043 miR-30b 0.41 0.004 0.046
miR-491-3p 2.56 0.041 0.025 miR-31 0.21 0.043 0.021
miR-519d 4.68 0.011 0.011 miR-381 0.45 0.003 0.066
miR-525-5p 2.57 0.009 0.072 miR-490-5p 0.36 0.032 0.042
miR-551a 3.31 0.012 0.183 miR-503 0.47 0.023 0.019
miR-574-5p 2.89 0.045 0.029 miR-510 0.21 0.046 0.081
miR-657 2.39 0.024 0.091 miR-542-3p 0.31 0.041 0.026
miR-662 3.21 0.045 0.017 miR-552 0.46 0.013 0.017
miR-768-3p 6.24 0.031 0.024 miR-553 0.33 0.031 0.198
miR-885-5p 2.66 0.015 0.053 miR-612 0.32 0.045 0.026
miR-890 2.93 0.036 0.302 miR-617 0.47 0.030 0.058
miR-96 2.38 0.031 0.082 miR-622 0.42 0.022 0.209
miR-625 0.17 0.051 0.094
miR-637 0.04 0.066 0.088
miR-654-3p 0.38 0.030 0.180
miR-769-5p 0.39 0.006 0.066
miR-801 0.32 0.001 0.027
miR-99b 0.38 0.003 0.061
Note: The threshold value used to screen up- and down-regulated miRNAs
was fold change >2.00 or fold change <0.50.
Table 2 miRNAs differentially expressed with vs. without
lanreotide treatment
Up regulated Down regulated
Name Fold P value FDR Name Fold P value FDR
miR-183 2.47 0.043 0.021 miR-124 0.25 0.024 0.005
miR-193a-5p 2.82 0.026 0.025 miR-32 0.41 0.031 0.082
miR-222 2.96 0.035 0.049 miR-574-5p 0.42 0.041 0.073
miR-516b 2.31 0.033 0.065 miR-744 0.31 0.025 0.158
miR-524-5p 2.49 0.021 0.011 miR-96 0.30 0.017 0.051
miR-601 2.58 0.030 0.094
miR-629 2.85 0.050 0.212
miR-99b 2.29 0.032 0.034
Note: The threshold value used to screen up- and down-regulated miRNAs
was fold change >2.00 or fold change <0.50.
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diction of miRNAs target genes can be analyzed using
four algorithms: TargetScan, PicTar, miRanda and miR-
Base Targets http://microrna.sanger.ac.uk/targets/. Using
these algorithms, we performed prediction analysis for
the target genes of the differentially expressed miRNAs
identified in microarray (miR-124, miR-125a-5p, miR-
125b, miR-126, miR-145, miR-151-3p, miR-524-5p, miR-
516b, miR-744 and miR-96). We also analyzed the target
genes of qRT-PCR confirmed miRNAs (miR-223, miR-
381, miR-503, miR-525-5p and miR-886-5p).
Discussion
GH-secreting pituitary adenoma and normal pituitary
Among the differentially expressed miRNAs between
GH-secreting pituitary adenomas and normal pituitary
samples, some are involved in cell growth, apoptosis,
cell proliferation and tumor development, as reported
by the previous studies [19-21]. Yu et al. [19] found that
ectopic overexpression of miR-184 resulted in a marked
increase in apoptosis and cell death. Meanwhile, Hino et
al. [20] demonstrated that miR-194 was involved in the
differentiation of intestinal epithelial cells. Ferretti et al.
[21] found that down-regulation of miR-125b caused the
proliferation of tumor cells. In our study, we found that
miR-126 and miR-381 were down-regulated in GH-
secreting pituitary adenomas compared to normal pitui-
tary. Previous study has shown that miR-126 is located
in the chromosome region of 9q34.3 and regulates phos-
phatidylinositol 3-kinase (PI3K) signaling by targeting
the PI3K regulatory subunit beta (p85b). Guo et al. [22]
reported that miR-126 modulated the activity of PI3K at
the level of signal initiation by limiting p85b levels in
the normal colon epithelium. Loss of miR-126 during
tumorigenesis would eliminate this check point and
facilitate the amplification of PI3K signal, which may
provide a growth advantage during colon carcinogenesis.
The target of miR-126 and miR-381 is PTTG protein 1,
which is involved in multiple cellular pathways, includ-
ing proliferation, DNA repair, transformation, angiogen-
esis induction, invasion, and the induction of genetic
instability. PTTG is overexpressed in most pituitary ade-
nomas and is correlated to the recurrence and angiogen-
esis [23]. Our results, therefore, indicated that altered
expression of miR-126 genes may play an important role
in the development of GH-secreting pituitary adenomas.
Tumor size
Among 9 differentially expressed miRNAs between
micro- and macro- GH-secreting pituitary adenomas,
the expression of miR-15a was down-regulated. There
was no correlation between the reduced expression of
miR-15a and tumor size (miR-15a, down-regulated, 0.32,
P =0 . 2 1 ,F D R=0 . 0 7 6 ,AP value >0.05, the data wasn’t
shown in the Table 1). This finding was supported by
previous study using the samples of corticotropinoma
[12]. Bottoni et al. [10] demonstrated an inverse correla-
tion between the tumor diameter and the expression
level of miR-15a and miR-16 in samples of GH- or PRL-
secreting pituitary adenomas, which was different from
Table 3 miRNAs differentially expressed in macro- vs.
micro- GH-secreting pituitary adenomas
Up regulated Down regulated
Name Fold P value FDR Name Fold P value FDR
miR-184 2.68 0.043 0.029 miR-124 0.43 0.031 0.005
miR-524-5p 2.85 0.021 0.027 miR-222 0.36 0.022 0.023
miR-629 2.49 0.015 0.061 miR-32 0.47 0.011 0.016
miR-766 2.17 0.031 0.033 miR-744 0.42 0.020 0.072
miR-765 0.41 0.042 0.173
Note: The threshold value used to screen up- and down-regulated miRNAs
was fold change >2.00 or fold change <0.50.
Figure 2 Cluster analysis shows a clear distinction between
macro- and microadenomas in GH-secreting pituitary
adenomas. Macroadenomas:1-18, Microadenomas:19-21.
Table 4 miRNAs differentially expressed in treatment
with GH responders vs. GH noresponders
Up regulated Down regulated
Name Fold P value FDR Name Fold P value FDR
miR-125b 2.73 0.034 0.013 miR-125a-5p 0.42 0.043 0.029
miR-886-5p 12.41 0.015 0.025 miR-198 0.46 0.012 0.005
miR-503 0.31 0.031 0.077
miR-524-5p 0.41 0.036 0.033
miR-630 0.42 0.022 0.095
Note: The threshold value used to screen up- and down-regulated miRNAs
was fold change >2.00 or fold change <0.50.
Figure 3 Cluster analysis shows a clear distinction between
SSA Responders and SSA Noresponders in GH-secreting
pituitary adenomas. SSA Responders:1-12, SSA Noresponders:13-15.
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reduced expression of miR-15a and miR-16 in the
pathogenesis of pituitary tumors. Consistent with these
results, enforced expression of the miR-222 can induce
the thyroid papillary carcinoma cell line to progress to
the S phase of the cell cycle, indicating that miR-222
negatively regulates p27Kip1 protein expression and cell
cycle [24]. Amaral et al. [12] found that the expression
of miR-21, miR-141 and miR-150 was reduced in corti-
cotropinomas. Patients with lower expression of miR-
141 had a higher chance of remission after transphenoi-
dal surgery, suggesting a possible role of the miR-141 in
the regulation of pituitary genes involved in tumor
growth and tumor local invasion. However, in this
study, we did not observe significant difference of miR-
21 and miR-141 expression between micro- and macro-
GH-secreting pituitary adenomas. Further studies are
needed to elucidate the pathogenesis of different subtype
pituitary tumors including GH-secreting pituitary
adenomas, PRL-secreting pituitary adenomas, and
corticotropinoma.
Lanreotide treatment and SSA responders or
nonresponders
Among the putative targets of miRNAs, miR-125a-5p,
miR-125b and miR-524-5p are associated with IGFBP-3
and IGFALS chain precursor, which are involved in pro-
tein binding, receptor binding, cell communication and
regulation of growth. The role of IGFALS is associated
with the regulation of the bioavailability of IGFs during
postnatal growth. Up to 90% of circulating IGF-I and
IGF-II are carried by binding to either IGFBP-3 or
IGFBP-5. ALS, in the form of tertiary complexes, can
extend their circulating half-life of IGF-I and IGF-II
[25]. Moreover, miR-524-5p targets matrix metallopro-
teinase-9, which is involved in metabolism, ion binding
and extracellular matrix. However, miR-524-5p was
down-regulated in SSA responders as compared to SSA
nonresponders. In contrast, miR-524-5p was up-regu-
lated in the lanreotide-treated patients as compared to
the untreated patients. The possible reason of miR-524-
5p up and down regulation in different groups is due to
the different responsiveness to SSA treatment in various
cases. The response to SSA depends on the presence of
a sufficiently high number of somatostatin receptors
(SSRs) (subtypes, sst1-5) on the tumor cells. GH secre-
tion is regulated through ligand binding of somatostatin
to both sst2 and sst5, whereas SSA binds preferentially
sst2 [26]. The GH-lowering effect of SSA is positively
correlated with the level of sst2 mRNA expression
[27-29]. Thus, in GH-responder cases, the level of
growth factor is high. Lanreotide is a type of inhibitory
growth factor. It is possible that miR-524-5p is nega-
tively correlated with growth factors, e.g., lanreotide pro-
motes miR-524-5p up regulation and inhibits the growth
factors. Another possible reason is that miR-524-5p is
inhibited itself by growth factor. When the inhibition is
removed (lanreotide treatment), the level of expression
of miR-524-5p is up-regulated. The similar reason may
explain the opposite phenomenon occurred with the
miR-193a-5p, miR-574-5p, miR-96 and miR-99b in
Table 2 and Table 5. However, further studies are
needed to elucidate the function and mechanisms of
altered expression of miR-524-5p.
Further analyses showed that miR-516b and miR-96
target IGFBP-7, miR-744 targets IGFBP-6, and miR-99b
targets homeobox protein prophet of Pit-1. All these
target genes are involved in the regulation of organ
development, nucleic acid binding and membrane-
bound organelles. Visvanathanet et al. [30] demonstrated
that SCP1 (small C-terminal domain phosphatase
Table 5 Some microarray data validation by qRT-PCR
Different miRNAs U6
Microarray Real time Microarray Real time
miR-124 0.54 0.39 1 1
miR-125a 1.26 1.95 1 1
miR-126 0.39 0.42 1 1
miR-223 2.78 1.42 1 1
miR-381 0.86 0.96 1 1
miR-503 0.22 0.37 1 1
miR-524-5P 0.28 0.34 1 1
miR-525-5p 5.14 4.05 1 1
miR-886-5P 3.71 1.51 1 1
miR-125b 2.85 1.92 1 1
miR-145 1.60 1.76 1 1
miR-151-3p 1.16 0.91 1 1
miR-183 1.20 1.59 1 1
miR-184 0.63 0.77 1 1
miR-193a-5p 0.62 0.73 1 1
miR-194 1.11 0.84 1 1
miR-198 0.46 0.49 1 1
miR-222 1.12 1.42 1 1
miR-30b 0.49 1.11 1 1
miR-32 1.64 1.03 1 1
miR-516b 0.64 0.87 1 1
miR-574-5p 1.10 1.15 1 1
miR-601 0.53 0.79 1 1
miR-629 0.45 0.31 1 1
miR-630 0.38 0.48 1 1
miR-744 2.03 1.74 1 1
miR-765 1.49 2.11 1 1
miR-766 0.57 0.47 1 1
miR-96 1.85 2.23 1 1
miR-99b 2.53 1.19 1 1
Note: Relative miRNA mean levels in pituitary adenomas were evaluated by
quantitative real time PCR in three individual experiments.
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Page 6 of 81) played an anti-neural role during CNS development.
miR-124 can inhibit SCP1 expression by directly target-
ing SCP1-3’ untranslated region (UTR). It is suggested
that during CNS development, timely down-regulation
of SCP1 is critical for induction of neurogenesis. Contri-
bution of miR-124 to this proce s si sa tl e a s tp a r t i a l l y
through down-regulation of SCP1 expression. These
results also implied that establishing a novel evolutiona-
rily conserved strategy to keep the balance between
miRNAs and their transcriptional regulatory programs is
necessary.
miR-145 was down-regulated in GH-secreting pitui-
tary adenomas as compared to normal pituitary. Amaral
et al. [12] observed that miR-145 was down-regulated in
11 samples of corticotropinomas, suggesting a possible
role of miR-145 in carcinogenesis. The potential target
genes of miR-145 encode oncogenic proteins, such as
m y c ,k r a s ,f o s ,y e s , fli, cyclin D2, and MAPK transduc-
tion proteins [31]. miR-145 targets the insulin receptor
substrate-1 (IRS-1) and miR-151-3p targets the insulin
receptor substrate-4 (IRS-4), which regulated cell com-
munication, receptor and membrane activities. Further-
more, Shi et al. [32] demonstrated experimentally that
miR145 targeted IRS-1 and had a profound biological
effect on human colon cancer cells. IRS-1, a docking
protein for both the type 1 insulin-like growth factor
receptor (IGF-IR) and the insulin receptor, is known to
transmit a mitogenic, anti-apoptotic, and anti-differen-
tiation signal.
Some of the miRNAs in our study, such as miR-769-
5p, miR-885-5p, miR-886-5p and miR-890 are newly
discovered in pituitary adenomas samples because the
new array contains more capture probes and their func-
tions are unknown [33]. The differentially expressed
miRNAs are correlated with adenoma characteristics. In
this study, the sample size is relatively low, and 4
months of treatment is relatively short. However, it
must be emphasized that our studies represent promis-
ing preliminary results. Therefore, further studies are
needed to predict up-regulated or down-regulated miR-
NAs target genes and their correlation with GH-secret-
ing pituitary adenomas characteristics.
In conclusion, our results indicated that altered miR-
NAs expression may be involved in GH-secreting pitui-
tary adenomas transformation. Furthermore, some
differentially expressed miRNAs are associated with
tumor diameter, lanreotide treatment, and responsive-
ness to SSA. These results will facilitate our understand-
ing on mechanism of SSA treatment for acromegaly.
Further studies are needed to predict the up-regulated
or down-regulated miRNAs’ targets and their partner
factors in pituitary adenomas. Studying the targets of
deregulated miRNAs may elucidate molecular mechan-
isms involved in pituitary adenoma pathogenesis.
Additional material
Additional file 1: Table S1 and S2. Supplemental tables
Additional file 2: Figure S1. Diagnosis of GH-secreting pituitary
adenoma with H&E and immunohistochemical staining. Panel A
indicated the microphotographs with H&E staining for growth hormone
pituitary adenoma sections. A strong and diffuse acidophilic staining was
shown in the cytoplasm of tumor cells. (original magnification, 200×).
Panel B indicated microphotographs of immunohistochemically stained
tumor sections, the tumor shows strong and diffuse staining for growth
hormone antigen (original magnification, 400×).
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